Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

White House Unveils Actions To Speed Precision Medicine

This article was originally published in Scrip

Executive Summary

The White House on Feb. 25 unveiled new actions and commitments from government agencies, including the National Institutes of Health (NIH) and the FDA, and private-sector participants, including Pfizer Inc. and Roche AG unit Genentech Inc., aimed at speeding President Barack Obama's Precision Medicine Initiative (PMI) forward.

You may also be interested in...



'App-A-Thon' Aims To Create PrecisionFDA Software Library To Advance Next-Gen Sequencing

US FDA is challenging stakeholders to develop apps that users of its precisionFDA platform can leverage to advance next-generation sequencing technology. Results from the competition will be announced by Commissioner Robert Califf next month in Washington, DC.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Allergan's Price Reform Pledge: Will Others Follow?

Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC064588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel